Nature Reviews Neurology provides physicians and academics with authoritative and topical discussions of key developments in the field.
378 followers 1 article/week
Author Correction: The complex aetiology of cerebral palsy

Nature Reviews Neurology, Published online: 25 April 2024; doi:10.1038/s41582-024-00964-wAuthor Correction: The complex aetiology of cerebral palsy

Fri Apr 26, 2024 00:49
Neuronal activity drives glymphatic waste clearance

Nature Reviews Neurology, Published online: 15 April 2024; doi:10.1038/s41582-024-00963-xTwo new studies show that clearance of waste, including pathogenic amyloid, through the glymphatic system is driven by synchronized neuronal activity.

Tue Apr 16, 2024 00:44
Addressing disparities in neurology by identifying gaps in hospital care

Nature Reviews Neurology, Published online: 12 April 2024; doi:10.1038/s41582-024-00960-0Nature Reviews Neurology is interviewing individuals who are driving efforts to address disparities in neurology through a broad spectrum of diversity, equity and inclusion initiatives. We spoke with neurosurgeon Sonia Mejía Pérez from Mexico about her work to address...

Fri Apr 12, 2024 21:49
Neurofilaments as biomarkers in neurological disorders — towards clinical application

Nature Reviews Neurology, Published online: 12 April 2024; doi:10.1038/s41582-024-00955-xNeurofilaments have been validated as specific body fluid biomarkers of neuro-axonal injury. In this Review, Khalil and colleagues provide an update on the structure and function of neurofilaments, analytical approaches and challenges in different clinical contexts,...

Fri Apr 12, 2024 21:49
EBV-specific T cells in multiple sclerosis

Nature Reviews Neurology, Published online: 10 April 2024; doi:10.1038/s41582-024-00959-7New data recently reported at the ACTRIMS Forum add to growing evidence of an aetiological role for Epstein–Barr virus infection in multiple sclerosis.

Wed Apr 10, 2024 07:02
BTK inhibitor falters in multiple sclerosis trials

Nature Reviews Neurology, Published online: 10 April 2024; doi:10.1038/s41582-024-00958-8Findings of phase III trials of the Bruton’s tyrosine kinase inhibitor evobrutinib in patients with relapsing multiple sclerosis were recently presented at the ACTRIMS Forum.

Wed Apr 10, 2024 07:02

Build your own newsfeed

Ready to give it a go?
Start a 14-day trial, no credit card required.

Create account